Ceftriaxone effect on bilirubin-albumin binding

Area of Science:

• Pharmacology
• Neonatal Medicine
• Biochemistry

Background:

• Bilirubin-albumin binding is crucial for preventing bilirubin neurotoxicity.
• Ceftriaxone is a widely used antibiotic in neonates.
• Premature infants are particularly vulnerable to bilirubin-induced brain damage.

Purpose of the Study:

• To investigate the in vitro effect of ceftriaxone on bilirubin-albumin binding.
• To quantify the impact of ceftriaxone on albumin's reserve binding capacity in newborn serum.

Main Methods:

• In vitro studies using peroxidase and dialysis rate methods.
• Assessed binding interactions between ceftriaxone, bilirubin, and human serum albumin.
• Utilized adult and newborn serum samples.

Main Results:

• Ceftriaxone competes with bilirubin for binding sites on human serum albumin.
• The displacement constant for ceftriaxone is 1.5 X 10(4) L/mol.
• Therapeutic ceftriaxone levels reduced the reserve albumin concentration in newborn serum by 39%.

Conclusions:

• Ceftriaxone significantly impairs bilirubin-albumin binding.
• This interaction may elevate the risk of bilirubin encephalopathy in jaundiced premature infants.
• Clinical caution is advised when administering ceftriaxone to neonates with jaundice.